Key clinical point: A chimeric antigen receptor (CAR) T-cell cocktail targeting both CD19 and CD22 could improve outcomes for patients with refractory or relapsed B-cell malignancies.
Major finding: Among patients with B-cell acute lymphoblastic leukemia, minimal residual disease-negative complete response rate was 96%.
Study details: An open-label, single-arm pilot study involving 89 patients with refractory/relapsed B cell malignancies.
Disclosures: The investigators reported having no conflicts of interest.
Wang N et al. 2019 Oct 29. doi: 10.1182/blood.2019000017.